TD Cowen analyst Itay Michaeli lowered the firm’s price target on Cerence (CRNC) to $10 from $11.50 and keeps a Hold rating on the shares. Though the firm remains constructive on the GenAI penetration story and Cerence’s positioning after the company reported a fiscal Q2 beat and revised up its FY25 EBITDA and cash flow guidance, TD notes it lowered its price target on lower auto production forecasts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNC:
- Cerence Inc. Surpasses Earnings Expectations with Strong Q2 Performance
- Cerence price target lowered to $10 from $12 at Wells Fargo
- Buy Rating for Cerence Amid Strong Performance and Strategic Positioning Despite Tariff Uncertainties
- Cerence Inc. Surpasses Earnings Expectations in Q2 2025
- Cerence reports Q2 EPS 46c, consensus 30c